Related Experiment Video
Updated: Jun 12, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
[Study progress on serogroup B meningococcal vaccine]
1Institute of Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Abstract:
Meningococcal disease, caused by Neisseria meningitidis (Nm), is still one serious threatening infectious disease with high mortality. Vaccination is available for prevention and control of such disease. Based on the chemical structure of capsule polysaccharide, Nm strains were classified into 13 serogroups. Meningococcal polysaccharide vaccines and polysaccharide conjugated protein vaccine against serogroup A, C, W135 and Y were efficacious and have been widely used. Because of poor immunogenicity and the structurally homologous with neural cell, capsule polysaccharide of serogroup B Nm can not be used as vaccine candidate. In last several decades, B group vaccines develoment focused on the proteins research. Based on the out membrane protein and reverse vaccinology technology, progress of B group vaccine were accelerated. Several meningococcal B vaccine showed favorable immunogenicity and efficacity. Some B vaccines have been licensed and widely used.
Insights
Meningococcal disease remains a threat, but vaccines targeting serogroups A, C, W135, and Y are effective. Research is advancing serogroup B vaccines using protein-based strategies and reverse vaccinology.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Context:
- Meningococcal disease, caused by Neisseria meningitidis (Nm), is a significant infectious disease with high mortality.
- Current vaccines are available for serogroups A, C, W135, and Y, but serogroup B remains a challenge due to vaccine development hurdles.
Purpose:
- To review the development of vaccines against Neisseria meningitidis, focusing on challenges and advancements in serogroup B vaccine development.
- To highlight the shift towards protein-based vaccines and reverse vaccinology for Neisseria meningitidis serogroup B.
Summary:
- Neisseria meningitidis (Nm) causes a life-threatening infectious disease. While polysaccharide-based vaccines are effective against several serogroups, serogroup B vaccine development has been hindered by poor immunogenicity and molecular mimicry concerns.
- Recent advancements in reverse vaccinology and outer membrane protein research have accelerated the development of serogroup B meningococcal vaccines.
- Several serogroup B meningococcal vaccines have demonstrated favorable immunogenicity and efficacy, with some now licensed and in use.
Impact:
- The development of effective serogroup B meningococcal vaccines addresses a critical unmet need in disease prevention.
- Advancements in reverse vaccinology offer a promising platform for developing vaccines against other challenging pathogens.
- Increased vaccine availability for serogroup B will contribute to reducing the global burden of meningococcal disease.
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis
Bacterial Meningitis II: Pathophysiology
Vaccine Production
Cryptococcal Meningitis
Viral Meningitis

